|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
03-19-2010, 12:26 PM
|
|||
|
|||
Human Genome Sciences Announces Results Of Randomized Phase 2 Trial Of Mapatumumab In
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). The results showed no difference in disease response or progression-free survival for the combination that included mapatumumab vs ...
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Human Genome Sciences says cancer drug fails study | cancerfr | Bone Cancer | 0 | 06-09-2010 10:27 PM |
| Celldex Therapeutics Announces Initiation of Randomized Phase 2 Clinical Trial of CDX | cancerfr | Bladder Cancer | 0 | 05-17-2010 10:01 PM |
| Positive Interim Results for JX-594 Randomized Phase 2 Liver Cancer Trial Presented a | cancerfr | Liver Cancer | 0 | 04-19-2010 10:28 PM |
Linear Mode
